LONDON – GSK plc has entered into a definitive agreement to acquire Boston-based biopharmaceutical firm Nuvalent, Inc. for $10.6 billion, marking a significant expansion of the company’s oncology portfolio into the non-small cell lung cancer (NSCLC) market.
The transaction, announced June 10, 2026, is designed to integrate high-selectivity kinase inhibitors into GSK’s pipeline to address specific efficacy and tolerability gaps in current standard-of-care therapies. The deal provides GSK with three targeted lung cancer assets, including two late-stage candidates currently under review by the US Food and Drug Administration.
Strategically, the acquisition serves as a hedge against the anticipated loss of exclusivity for dolutegravir between 2028 and 2030. By securing assets with validated targets, GSK aims to maintain its core operating profit and revenue trajectory toward a group target of more than £40 billion in annual sales by 2031, while further rebalancing the business mix toward oncology.
Transaction Terms and Financial Structure
GSK will execute a tender offer to acquire all outstanding Class A and Class B common stock of Nuvalent at a cash price of $124 per share. This valuation represents a 40% premium over the last closing price and a 26% premium relative to the 30-day volume-weighted average price, underscoring the strategic value GSK is assigning to Nuvalent’s late-stage pipeline rather than its current revenue base.
| Metric | Value (USD) | Value (GBP) |
|---|---|---|
| Aggregate Equity Value | $10.6 Billion | £8.0 Billion |
| Net Investment (Net of Cash) | $9.4 Billion | £7.1 Billion |
| Offer Price per Share | $124.00 | – |
The acquisition will be funded through a combination of cash and new and existing debt facilities. GSK has stated the financing will not impact its investment-grade credit rating, and the company maintains its commitment to a 70p dividend for 2026, signalling to shareholders that the transaction is being managed within existing capital-allocation priorities.
Clinical Pipeline and Market Entry
The acquisition centers on Nuvalent’s precision medicine capabilities, specifically targeting ROS1, ALK, and HER2 alterations in NSCLC-genetic drivers that account for a subset of patients who often cycle through multiple lines of therapy due to resistance or tolerability issues. The two lead assets, zidesamtinib (NVL-520) and neladalkib (NVL-655), have both received Breakthrough Therapy and Orphan Drug Designations, positioning them for potential expedited development and review timelines.
GSK expects regulatory decisions on these assets by September 18, 2026, for zidesamtinib and November 27, 2026, for neladalkib. If approved, both are slated for a 2026 commercial launch with “multi-blockbuster” potential in their respective molecularly defined segments of the lung cancer market. A third asset, the HER2 inhibitor NVL-330, is currently in phase I trials and is expected to support a longer-term life-cycle strategy in HER2-mutant NSCLC.
“Today’s acquisition is a multi-product deal, consistent with our approach to acquire assets that have clinically proven targets and meaningfully address an efficacy and/or tolerability gap. The two lead products are potential best-in-class assets that could launch this year if approved by the FDA and offer significant new treatment options to patients with two forms of non-small cell lung cancer,” said Luke Miels, Chief Executive Officer of GSK.
The Nuvalent portfolio provides a complementary platform for GSK’s existing development of Ris-Rez, a B7-H3 targeted antibody-drug conjugate (ADC) currently in phase III trials, and is expected to deepen GSK’s presence in both small-molecule and biologics-based oncology approaches.
Earnings Impact and Governance
While the transaction is expected to cause low single-digit percentage dilution to core earnings per share (EPS) for the current fiscal year, 2027, and 2028, GSK projects the deal will become accretive to sales and core operating profit by 2027. Full accretion to core EPS is anticipated by 2029, factoring in cost and portfolio synergies, integration efficiencies and a reprioritisation of internal R&D spend toward oncology.
The company’s 2026 full-year guidance remains unchanged, with core operating profit and core EPS growth forecasted in the 7-9% range, indicating that management views the acquisition as complementary rather than transformative to near-term financial performance.
As part of the merger, GSK will assume existing revenue-sharing obligations, including low-single-digit royalties payable to Deerfield and Royalty Pharma, which will sit alongside any future milestone or post-marketing commitments associated with Nuvalent’s pipeline.
The transaction is subject to the tender of a majority of Nuvalent’s Class A common stock and the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act in the United States. Following the tender offer, GSK intends to acquire any remaining NASDAQ-listed shares via a second-step merger under Delaware law, after which Nuvalent would be delisted and operate as a wholly owned subsidiary within GSK’s oncology business.
